Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

NEVARAPINE

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

27 API Suppliers, 18 USDMF, 11 CEP/COS, 1 JDMF, 4 EU WC, 9 NDC API, 8 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

22 Drugs in Development

22 Drugs in Development

INTERMEDIATES

13 Intermediate Suppliers

13 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

158 FDF Dossiers, 60 FDA Orange Book, 52 Europe, 4 Canada, 2 Australia, 26 South Africa, 14 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 100MG, TABLET, EXTENDED RELEASE;ORAL - 400MG, TABLET;ORAL - 150MG;200MG;300MG, TABLET;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SUSPENSION;ORAL - 50MG/5ML

RELATED EXCIPIENT COMPANIES

1 Minakem, 5 SPI Pharma, 4 DKSH, 6 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 1 ACG Worldwide, 1 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 11 BASF, 10 Corel Pharma Chem, 7 DFE Pharma, 7 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 4 Ideal Cures, 4 Ingredion Pharma Solutions, 23 Kerry, 3 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 13 Microlex e.U, 3 Nitika Pharmaceutical Specialities, 3 Novo Excipients, 4 Pharmatrans-Sanaq, 5 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 16 Roquette, 7 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 11 Sigachi Industries, 4 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

58 Fillers, Diluents & Binders, 37 Coating Systems & Additives, 31 Direct Compression, 28 Disintegrants & Superdisintegrants, 27 Granulation, 21 Lubricants & Glidants, 19 Controlled & Modified Release, 16 Thickeners and Stabilizers, 12 Co-Processed Excipients, 10 Solubilizers, 8 Film Formers & Plasticizers, 8 Taste Masking, 8 Chewable & Orodispersible Aids, 6 Rheology Modifiers, 5 Empty Capsules, 5 API Stability Enhancers, 4 Vegetarian Capsules, 4 Emulsifying Agents, 3 Parenteral, 2 Coloring Agents

DIGITAL CONTENT

11 News #PharmaBuzz

11 News #PharmaBuzz

GLOBAL SALES INFORMATION

7 US Medicaid Prescriptions, 19 Regulatory FDF Prices

MARKET PLACE

8 APIs, 6 FDF Dossiers

PATENTS & EXCLUSIVITIES

1 US Patents, 2 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 2 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
29/11/2025	Aurobindo Pharma Limited	India	APITORIA PHARMA PRIVATE LIMITED Hyderabad IN	CEP 2012-184 - Rev 02	Nevirapine, Process II	2024-01-12	Valid	Chemical		2255
29/11/2025	Aurobindo Pharma Limited	India	APITORIA PHARMA PRIVATE LIMITED Hyderabad IN	CEP 2024-062 - Rev 00	Nevirapine hemihydrate	2024-08-08	Valid	Chemical		2479

NEVARAPINE

NEVARAPINE

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

27 API Suppliers

18 USDMF

11 CEP/COS

1 JDMF

4 EU WC

9 NDC API

8 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

22 Drugs in Development

INTERMEDIATES

13 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

158 FDF Dossiers

60 FDA Orange Book

52 Europe

4 Canada

2 Australia

26 South Africa

14 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 100MG

TABLET, EXTENDED RELEASE;ORAL - 400MG

TABLET;ORAL - 150MG;200MG;300MG

TABLET;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SUSPENSION;ORAL - 50MG/5ML

RELATED EXCIPIENT COMPANIES

1 Minakem

5 SPI Pharma

4 DKSH

6 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

1 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

1 ACG Worldwide

1 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Ashland

11 BASF

10 Corel Pharma Chem

7 DFE Pharma

7 Gangwal Chemicals

1 Huzhou Sunflower Pharmaceutical

4 Ideal Cures

4 Ingredion Pharma Solutions

23 Kerry

3 Keval Exports

3 Kima Chemical

6 Lonza Capsugel

13 Microlex e.U

3 Nitika Pharmaceutical Specialities

3 Novo Excipients

4 Pharmatrans-Sanaq

5 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

16 Roquette

7 Seppic

6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

11 Sigachi Industries

4 Silverline Chemicals

2 The Dow Chemical Company

1 Ulanqab Kema New Material

4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

58 Fillers, Diluents & Binders

37 Coating Systems & Additives

31 Direct Compression

28 Disintegrants & Superdisintegrants

TABLET;ORAL - 200MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons